[(2R,3R,4S,5R,6R)-6-[[(3aS,7R,7aS)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-(3,6-diaminohexanoylamino)-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [(2R,3R,4S,5R,6R)-6-[[(3aS,7R,7aS)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-(3,6-diaminohexanoylamino)-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate
• 化学式: C₁₉H₃₄N₈O₈
• 分子量: 502.5
• InChiKey: NRAUADCLPJTGSF-LLDRHZEUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.5
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  269
• 氢给体数：
  10
• 氢受体数：
  11

文献信息

• [EN] ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE<br/>[FR] CONJUGUÉS ANIONIQUES D'UN MÉTABOLITE BACTÉRIEN GLYCOSYLÉ
  申请人：GLYCAN BIOSCIENCES PTY LTD

  公开号：WO2010037179A1

  公开（公告）日：2010-04-08

  The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.

  该发明涉及与糖基化细菌代谢产物的阴离子结合物，可用于模拟被称为糖胺聚糖（GAGs）的阴离子生物活性分子的结构和/或活性。该发明还涉及制备这些结合物的过程。这些结合物在预防和/或治疗疾病条件方面具有用处，特别是慢性疾病条件，如炎症（包括过敏）疾病、转移性癌症和感染病原体（包括细菌、病毒或寄生虫）的情况。
• GLYCOPEPTIDE COMPOUNDS, METHODS FOR PRODUCING THE SAME, AND USES THEREOF
  申请人：Academia Sinica

  公开号：US20200291071A1

  公开（公告）日：2020-09-17

  Disclosed herein are novel compounds and uses thereof. The present compounds are useful in suppressing the growth of various bacteria, including gram-positive and gram-negative bacteria. Accordingly, these compounds may be used to manufacture a medicament or pharmaceutic composition for treating disease and/or disorders associated with bacterial infection, especially antibiotic-resistant bacterial infection. Al so disclosed herein are methods for treating infectious diseases by use of the present compounds, medicament or pharmaceutical composition.

  本文披露了新颖的化合物及其用途。这些化合物可用于抑制各种细菌的生长，包括革兰氏阳性和阴性细菌。因此，这些化合物可用于制造治疗与细菌感染有关的疾病和/或疾病的药物或药学组合物，特别是抗生素耐药性细菌感染。本文还披露了利用这些化合物、药物或药学组合物治疗传染病的方法。
• New streptothricin-group compounds
  申请人：AJINOMOTO CO., INC.

  公开号：EP0096552A1

  公开（公告）日：1983-12-21

  There are disclosed streptothricin-group compounds having the following formula: wherein R represents The compounds are produced by the aerobic culture of Streptomyces nojiriensis FERM-BP 287.

  公开了具有下式的链霉毒素类化合物： 其中 R 代表 该化合物由诺尻链霉菌 FERM-BP 287 的需氧培养产生。
• Processes and host cells for genome, pathway, and biomolecular engineering
  申请人：enEvolv, Inc.

  公开号：US10370654B2

  公开（公告）日：2019-08-06

  The present disclosure provides compositions and methods for genomic engineering.

  本公开提供了基因组工程的组合物和方法。
• Dominant selectable marker for gene transformation and disruption in yeasts
  申请人：——

  公开号：US20010031724A1

  公开（公告）日：2001-10-18

  The present invention provides a novel dominant selectable marker system in yeast that is based on an aminoglycoside, nourseothricin (NST). This compound possesses a powerful antifungal activity against Candida albicans and S. cerevisiae . The invention provides a cognate drug resistance marker for use in gene transformation and disruption experimentation in Candida albicans and Saccharomyces cerevisiae . In particular, the invention presents: 1) direct utility for gene manipulations in both clinically and experimentally relevant strains regardless of genotype and without affecting growth rate, or hyphal formation; and 2) applicability to antifungal drug discovery, including target validation and various forms of drug screening assays.

  本发明提供了一种新型的酵母显性可选择标记系统，该系统基于氨基糖苷--诺索三嗪（NST）。这种化合物具有强大的抗真菌活性，能抑制 白色念珠菌 和 酵母菌 .本发明提供了一种同源抗药性标记，可用于白念珠菌的基因转化和破坏实验。 白色念珠菌 和 酿酒酵母 .特别是，本发明提出了1) 直接用于临床和实验相关菌株的基因操作，无论基因型如何，且不影响生长速度或菌丝形成；以及 2) 适用于抗真菌药物发现，包括靶点验证和各种形式的药物筛选试验。